Table 1.
DR categorisation and clinicopathological characteristics
| DR pattern | |||||
|---|---|---|---|---|---|
| Parameters | Categories | Mature (N = 638) | Intermediate (N = 294) | Immature (N = 59) | P value |
| Gender | Male | 386 (60.5) | 181 (61.6) | 34 (57.6) | 0.8460 |
| Female | 252 (39.5) | 113 (38.4) | 25 (42.4) | ||
| Age (average; years) | 65.5 | 65.5 | 64.9 | 0.7373 | |
| Tumour location | Rt-sided colon | 270 (42.3) | 116 (39.5) | 19 (32.2) | 0.0566 |
| Lt-sided colon | 264 (41.4) | 109 (37.1) | 29 (49.2) | ||
| Rectosigmoid | 104 (16.3) | 69 (23.5) | 11 (18.6) | ||
| Maximum diameter (mm) | 49.7 | 47.5 | 46.1 | 0.6829 | |
| No. of examined LNs (average) | 20.5 | 19.7 | 18.7 | 0.4395 | |
| No. of examined LNs | ≤11 | 148 (23.2) | 77 (26.2) | 17 (28.8) | 0.4420 |
| ≥12 | 490 (76.8) | 217 (73.8) | 42 (71.2) | ||
| Tumour differentiation | G1 | 292 (45.8) | 106 (36.1) | 22 (37.3) | 0.0211 |
| G2 | 321 (50.3) | 169 (57.5) | 36 (61.0) | ||
| G3 | 25 (3.9) | 19 (6.5) | 1 (1.7) | ||
| T-stage | T3 | 570 (89.3) | 220 (74.8) | 33 (55.9) | <0.0001 |
| T4 | 68 (10.7) | 74 (25.2) | 26 (44.1) | ||
| Lymphatic invasion | Negative | 286 (44.8) | 108 (36.7) | 22 (37.3) | 0.0503 |
| Positive | 352 (55.2) | 186 (63.3) | 37 (62.7) | ||
| Venous invasion | Negative | 265 (41.5) | 98 (33.3) | 23 (39.0) | 0.0580 |
| Positive | 373 (58.5) | 196 (66.7) | 36 (61.0) | ||
| Tumour budding | BD1 | 317 (49.7) | 57 (19.4) | 2 (3.4) | <0.0001 |
| BD2 | 220 (34.5) | 102 (34.7) | 9 (15.3) | ||
| BD3 | 101 (15.8) | 135 (45.9) | 48 (81.4) | ||
| Preoperative CEA (ng/ml) | ≤5.0 | 459 (71.9) | 181 (61.6) | 30 (50.8) | <0.0001 |
| >5.0 | 152 (23.8) | 98 (33.3) | 26 (44.1) | ||
| Not available | 27 (4.2) | 15 (5.1) | 3 (5.1) | ||
| MSI | MSI-high | 48 (7.5) | 19 (6.5) | 2 (3.4) | 0.2190 |
| MSI-low/MSS | 573 (89.8) | 262 (89.1) | 57 (96.6) | ||
| Not available | 17 (2.7) | 13 (4.4) | 0 (0.0) | ||
| Treatment arm | Surgery-alone | 320 (50.2) | 144 (49.0) | 37 (62.7) | 0.1480 |
| UFT | 318 (49.8) | 150 (51.0) | 22 (37.3) | ||
DR desmoplastic reaction, LN lymph node, CEA carcinoembryonic antigen, MSI microsatellite instability, MSS microsatellite stable, UFT tegafur–uracil.